Please provide your email address to receive an email when new articles are posted on . New therapies, like drugs for glomerular diseases and kidney replacement devices, offer potential for treating ...

On the first day of ASN 2025 Kidney Week, Dr Sumeska Thavarajah reports on several clinical trials in kidney disease that were presented, notably including a phase 2 study of rilparencel, a stem cell ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON, Nov. 4, 2025 ...

Interim results from a phase III trial were presented at the Kidney Week meeting ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in ...

After attending the ASN 2025 Kidney Week, Dr Sumeska Thavarajah reflects on the exciting developments in nephrology, particularly the emergence of new drugs entering advanced clinical trials. The ...